Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: Results from the PPP-Botnia Study

Annals of Medicine

Volumn 44, Issue 3, 2012, Pages 279-288

  Pyykkönen, Antti Jussi ^a,b   Räikkönen, Katri ^a   Tuomi, Tiinamaija ^b,c   Eriksson, Johan G ^a,b,c,d,e   Groop, Leif ^c,f   Isomaa, Bo ^b,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e VAASA CENTRAL HOSPITAL   (Finland)

^f LUND UNIVERSITY   (Sweden)

^g Lund University ^*  (Finland)

Author keywords

Antidepressive agents; Depression; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS SURGERY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; DEPRESSION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 84859365690     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.543921     Document Type: Article

References (36)

1. Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: Gender-dependent associations. Depress Anxiety. 2008;25:661-9.
2. Vogelzangs N, Suthers K, Ferrucci L, SimonsickEM, Ble A, Schrager M, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology. 2007;32:151-9. (Pubitemid 46274017)
3. Vaccarino V, McClure C, Johnson BD, Sheps DS, Bittner V, Rutledge T, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med. 2008;70:40-8.
4. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: Findings from the third national health and nutrition examination survey. Psychosom Med. 2004;66:316-22. (Pubitemid 38668398)
5. Raikkonen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: A comparison of world health organization, adult treatment panel III, and international diabetes foundation defi nitions. Diabetes Care. 2007;30:872-7. (Pubitemid 46556580)
6. Vanhala M, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Koponen H. Depressive symptoms predispose females to metabolic syndrome: A 7-year follow-up study. ActaPsychiatr Scand. 2009;119:137-42.
7. Arroyo C, Hu FB, Ryan LM, Kawachi I, Colditz GA, Speizer FE, et al. Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care. 2004;27:129-33. (Pubitemid 38196721)
8. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006; 49:837-45.
9. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9. (Pubitemid 32893993)
11. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested defi nitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-7. (Pubitemid 35396938)
12. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31:420-6.
13. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64 Suppl 8:22-9. (Pubitemid 36903904)
14. Lustman PJ, Griffi th LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59:241-50. (Pubitemid 27240725)
15. Isomaa B, Forsen B, Lahti K, Holmstrom N, Waden J, Matintupa O, et al. A family history of diabetes is associated with reduced physical fi tness in the prevalence, prediction and prevention of diabetes (PPP)-botnia study. Diabetologia. 2010;53:1709-13.
16. Pyykkonen AJ, Raikkonen K, Tuomi T, Eriksson JG, Groop L, Isomaa B. Stressful life events and the metabolic syndrome: The prevalence, prediction and prevention of diabetes (PPP)-botnia study. Diabetes Care. 2010;33: 378-84.
17. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304. (Pubitemid 41242486)
18. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO expert consultation. Diabetologia. 2010;53:600-5.
19. Alberti KG, Zimmet PZ. Defi nition, diagnosis and classifi cation of diabetes mellitus and its complications. Part 1: Diagnosis and classifi cation of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53. (Pubitemid 28319935)
20. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis. 2007;194:1-45. (Pubitemid 47470068)
21. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ. 1993;2:217-27.
22. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: Manual interpretation and guide. Boston: Nimrod Press; 1993.
23. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, Weinstein MC. Performance of a fi ve-item mental health screening test. Med Care. 1991;29:169-76.
24. Aalto A, Aro AR, Teperi J. RAND-36 as a measure of healthrelated quality of life. reliability, construct validity and reference values in the Finnish general population. Helsinki: STAKES; 1999.
25. Salonen JT, Lakka TA. Assessment of physical activity in population studies-validity and consistency of the methods in the Kuopio ischemic heart disease risk factor study. Scand J Sports Sci. 1987;9:89-95. (Pubitemid 18037632)
26. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torrens JI, Kravitz HM, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27:2856-62. (Pubitemid 39565049)
27. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: Does cortisol play a role? Biol Psychiatry. 2004;55:1-9. (Pubitemid 38045427)
28. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, et al. Adrenocortical, autonomic, and infl ammatory causes of the metabolic syndrome: Nested case-control study. Circulation. 2002;106:2659-65. (Pubitemid 35364919)
29. Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJ, DeRijk RH, et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab. 2010;95:2458-66.
30. Flory JD, Manuck SB, Matthews KA, Muldoon MF. Serotonergic function in the central nervous system is associated with daily ratings of positive mood. Psychiatry Res. 2004; 129:11-19. (Pubitemid 39574433)
31. Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I. Infl ammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry. 2010; 71:1007-16.
32. Raikkonen K, Pesonen AK, Kajantie E, Heinonen K, Forsen T, Phillips DI, et al. Length of gestation and depressive symptoms at age 60 years. Br J Psychiatry. 2007;190:469-74. (Pubitemid 46868829)
33. Eriksson JG, Osmond C, Kajantie E, Forsen TJ, Barker DJ. Patterns of growth among children who later develop type 2 diabetes or its risk factors. Diabetologia. 2006; 49:2853-8. (Pubitemid 44730287)
34. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: A population-based 7-year followup study. J Clin Psychiatry. 2008;69:178-82. (Pubitemid 351469259)
35. Akbaraly TN, Kivimaki M, Brunner EJ, Chandola T, Marmot MG, Singh-Manoux A, et al. Association between metabolic syndrome and depressive symptoms in middleaged adults: Results from the Whitehall II study. Diabetes Care. 2009;32:499-504.
36. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: Antecedent or consequence? Metabolism. 2002;51:1573-7. (Pubitemid 36018831)